Central Garden & Pet Company (CENT)

NASDAQConsumer StaplesPackaged FoodsSnapshot 2026-10-23

$45.38+0.55%

Close 2026-10-23 · 1-day change

Investment OutlookAs of Oct 24, 2026

What could strengthen or challenge Central Garden & Pet Company’s outlook?

The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Oct 4, 2026.

Higher potential upsideImproving expectations

Next-FY EPS estimate change · 30 days

Comparable estimates unavailable

+10% or more+5%0%−5%−10% or less

A matching fiscal period and sufficient coverage are required.

Higher risk of downsideWeakening expectations

One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.

How this is measured

The calculation requires same-period, same-provider snapshots, positive EPS, at least five analysts and a baseline within three days of the requested lookback.

Measure / period	Management expectations	Analyst expectations
FY 2027 · Q1
Revenue	—	584M
EPS	—	0.13
FY 2026 · Annual
Capital expenditure	About $50M	—
FY 2027 · Annual
Revenue	—	2.94B
EPS	—	3.142
FY 2028 · Annual
Revenue	—	3.19B
EPS	—	3.321

What the Thesis Depends On

Three published thesis conditions, with dated milestones shown separately.

Key Factor	Why It Matters	Current Status	Break Condition	Latest Evidence
Maintain capital expenditures around $50 million annually	Capital spending remains disciplined at about $50 million.	Intact	Capex exceeds $60 million in FY26	Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Source date unavailableLast status assessment Oct 24, 2026Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement. Management context Stated in 5 of last 5 quarters. Management consistently projects capital expenditures around $50 to $60 million annually, with the latest guidance for fiscal 2026 at approximately $50 million. This reflects disciplined capital allocation focused on maintenance and growth. The trajectory is stable and consistent with management's stated discipline. Delivery assessment Oct 24, 2026
Raise fiscal 2026 non-GAAP diluted EPS to $2.85 or better	They raised EPS guidance to $2.85 for fiscal 2026.	Intact	EPS falls below $2.85 in FY26	Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Source date unavailableLast status assessment Oct 24, 2026Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement. Management context Stated in 3 of last 3 quarters. Management raised fiscal 2026 non-GAAP diluted EPS guidance from $2.70 or better to $2.85 or better in 2026-Q2, reflecting improved margin discipline and growth investments. The EPS guidance increase aligns with the trajectory of improving operating margins and earnings per share. Delivery assessment Oct 24, 2026
Improve operating margin to 14.3% or better	A supporting condition in Central Garden & Pet Company's published investment case. The stated target is >=14.3%.	Intact	Operating margin falls below 14.3%	Operating margin: 14.26% FY2026-Q3; GAAP. Published target: >=14.3%. Target period is not explicitly aligned with this observation. Source published Aug 6, 202614.262174 percent · calculatedSource reportLast status assessment Oct 24, 2026 Measurement source consolidated · GAAP FY2026-Q3 · Period ending Jun 27, 2026 Source: company_financial_results. Reference: 88e70b51-bc84-4de2-b14d-564679357ac4. Source status: eligible. Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement. Management context Newly stated in 2026-Q2. Management emphasized margin discipline and portfolio optimization as drivers for improved operating margins. Financials show operating margin expanded modestly from 14.1% in 2025-Q3 to 14.3% in 2026-Q3, indicating limited but positive progress on margin improvement. Delivery assessment Oct 24, 2026

Stored thesis · Oct 4, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.

Incoming Evidence

Compare these dated observations with the operating requirements above

Expectations trend

Same fiscal period

FY2028 · fiscal year ending 2028-09-27 · fmp

FY2028 EPS: comparable history unavailable.

FY2028 revenue: comparable history unavailable.

Exact estimates & source dates

One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.

FY2028 estimate observations · fmp
Snapshot	EPS	Revenue	EPS / revenue analysts
2026-09-28	Unavailable	Unavailable	1 / 1
2026-09-29	Unavailable	Unavailable	1 / 1
2026-09-30	Unavailable	Unavailable	1 / 1
2026-10-01	Unavailable	Unavailable	1 / 1
2026-10-02	Unavailable	Unavailable	1 / 1
2026-10-03	Unavailable	Unavailable	1 / 1
2026-10-04	Unavailable	Unavailable	1 / 1
2026-10-05	Unavailable	Unavailable	1 / 1
2026-10-06	Unavailable	Unavailable	1 / 1
2026-10-07	Unavailable	Unavailable	1 / 1
2026-10-08	Unavailable	Unavailable	1 / 1
2026-10-09	Unavailable	Unavailable	1 / 1
2026-10-10	Unavailable	Unavailable	1 / 1
2026-10-11	Unavailable	Unavailable	1 / 1
2026-10-12	Unavailable	Unavailable	1 / 1
2026-10-13	Unavailable	Unavailable	1 / 1
2026-10-14	Unavailable	Unavailable	1 / 1
2026-10-15	Unavailable	Unavailable	1 / 1
2026-10-16	Unavailable	Unavailable	1 / 1
2026-10-17	Unavailable	Unavailable	1 / 1
2026-10-18	Unavailable	Unavailable	1 / 1
2026-10-19	Unavailable	Unavailable	1 / 1
2026-10-20	Unavailable	Unavailable	1 / 1
2026-10-21	Unavailable	Unavailable	1 / 1
2026-10-22	Unavailable	Unavailable	1 / 1
2026-10-23	Unavailable	Unavailable	1 / 1
2026-10-24	Unavailable	Unavailable	1 / 1

Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.

Compare required revenue and earnings

Analyst view

Monthly observations

Buy / Strong BuyHoldSell / Strong Sell

Exact monthly counts

Monthly rating snapshots · fmp. Missing snapshots are not zero.
Date	Buy*	Sell*
2026-05-01	4	1
2026-06-01	4	1
2026-07-01	4	1
2026-08-01	4	1
2026-09-01	4	1
2026-10-01	4	1

*Buy includes Strong Buy; Sell includes Strong Sell. Monthly counts describe the analyst mix, not the firms behind each recent action.

Latest: 4 Buy / Strong Buy · 0 Hold · 1 Sell / Strong Sell

0 upgrades0 downgrades0 maintains

Recent actions · Sep 25–Oct 24 · 0 recorded

Price-target changes

30 days

Individual price-target observations are unavailable.

0 raises · 0 cuts · 0 unchanged · 0 without a comparable prior

How this is measured

Sep 25, 2026–Oct 24, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.

Outlook in Brief

The evidence, the remaining questions, and what comes next

What's improving

No recovery evidence is reported in the available driver assessments.

Still unresolved / key risks

Maintain capital expenditures around $50 million annuallyDirect metric needs a verified mapping
Raise fiscal 2026 non-GAAP diluted EPS to $2.85 or betterDirect metric needs a verified mapping
Improve operating margin to 14.3% or betterOperating margin: 14.26%

Next proof point

Nov 23, 2026

Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.

Review earnings

Bottom line

3 of 3 published conditions remain under pressure or need verification. The next results need to address those conditions.

The dated weekly assessment and its assumptions are available in Read detailed Outlook.

Historical risk context

Observed price history; separate from operating scenarios

Price sensitivity

0.9%Typical daily move · historical

Downside history

-16.4%Maximum drawdown · trailing year

Read detailed Outlook Company context, assumptions & risks

Central Garden & Pet Company outlook in detail

The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.

Updated Oct 24, 2026

What kind of bet this is

CENT is a consumer staples business with a mixed, execution-dependent long-term thesis rather than a clear durable compounder. The thesis is intact, and recent financial performance remains in the top half of its industry, but earnings quality is fragile.

What's priced into Central Garden & Pet Company

The evidence describes CENT as cheap versus peers, and its valuation has fallen from 61.5 to 50.1. The priced-in assessment is justified, with low fragility, while the expectations gap is negative; the evidence does not specify in detail what earnings expectations the market assumes.

What the fundamentals likely do

Near term, management’s raised fiscal 2026 non-GAAP diluted EPS outlook and recent earnings beat support the operating picture, while the acquisition’s financial effects are not expected until it closes in fiscal 2027. Earnings quality remains fragile, and a recent history of a deep miss warrants attention despite a low estimated near-term miss risk.

What Central Garden & Pet Company hinges on

The multi-year view depends partly on whether the TRIXIE acquisition expands CENT’s European pet supplies presence and delivers the intended strategic benefits. Near term, a guidance cut after the recent increase would damage credibility, while weakening employment or stronger results and guidance from sector peers could shift the sector backdrop.